Literature DB >> 21697339

Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans.

Alison Kuchta1, Taibur Rahman, Erica L Sennott, Taufiqur R Bhuyian, Taher Uddin, Rasheduzzaman Rashu, Fahima Chowdhury, Ashraf I Kahn, Mohammad Arifuzzaman, Ana A Weil, Michael Podolsky, Regina C LaRocque, Edward T Ryan, Stephen B Calderwood, Firdausi Qadri, Jason B Harris.   

Abstract

Vibrio cholerae O1 is a noninvasive enteric pathogen and serves as a model for studies of mucosal immunity. Although symptomatic V. cholerae infection induces durable protection against subsequent disease, vaccination with oral killed whole-cell V. cholerae stimulates less long-lasting protection against cholera. In this study, we demonstrated that cholera induces an early proinflammatory cellular immune response that results in priming of Th1- and Th17-type cytokine responses to ex vivo antigenic stimulation and an increase in the ratio of Th1 to Th2 CD4(+) T-cell responses. Comparable priming of Th1 and Th17 responses, with an increased ratio of Th1 to Th2 CD4(+) T-cell responses, was not observed in subjects who received two doses of the oral cholera vaccine Dukoral (a whole-cell cholera toxin B subunit containing [WC-CTB] vaccine). These findings suggest that natural V. cholerae infection induces an early, proinflammatory cellular immune response, despite the apparent lack of clinical signs of inflammation. The failure of the WC-CTB vaccine to activate equivalent, CD4(+) T-cell responses is a potential explanation for the shorter duration of protection following immunization with this vaccine. Additional studies are needed to determine whether these early T-cell-mediated events predict the subsequent duration of immunologic memory.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697339      PMCID: PMC3147337          DOI: 10.1128/CVI.05088-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  36 in total

Review 1.  Cholera as a model for research on mucosal immunity and development of oral vaccines.

Authors:  J Holmgren; C Czerkinsky
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

2.  CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin.

Authors:  E Hörnquist; D Grdic; T Mak; N Lycke
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Targeted vaccine adjuvants based on modified cholera toxin.

Authors:  Nils Lycke
Journal:  Curr Mol Med       Date:  2005-09       Impact factor: 2.222

4.  Refractory periods and climate forcing in cholera dynamics.

Authors:  Katia Koelle; Xavier Rodó; Mercedes Pascual; Md Yunus; Golam Mostafa
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses.

Authors:  Marie-Claire Gauduin
Journal:  Methods       Date:  2006-04       Impact factor: 3.608

6.  A Wilcoxon-type test for trend.

Authors:  J Cuzick
Journal:  Stat Med       Date:  1985 Jan-Mar       Impact factor: 2.373

Review 7.  Live attenuated oral cholera vaccines.

Authors:  Edward T Ryan; Stephen B Calderwood; Firdausi Qadri
Journal:  Expert Rev Vaccines       Date:  2006-08       Impact factor: 5.217

8.  Regulation of Th-1 T cell-dominated immunity to Neisseria meningitidis within the human mucosa.

Authors:  Victoria Davenport; Eleanor Groves; Christopher G Hobbs; Neil A Williams; Robert S Heyderman
Journal:  Cell Microbiol       Date:  2006-12-12       Impact factor: 3.715

9.  Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide.

Authors:  Richard Malley; Amit Srivastava; Marc Lipsitch; Claudette M Thompson; Claire Watkins; Arthur Tzianabos; Porter W Anderson
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

10.  Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up.

Authors:  J D Clemens; J R Harris; D A Sack; J Chakraborty; F Ahmed; B F Stanton; M U Khan; B A Kay; N Huda; M R Khan
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

View more
  23 in total

1.  Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera.

Authors:  Crystal N Ellis; Regina C LaRocque; Taher Uddin; Bryan Krastins; Leslie M Mayo-Smith; David Sarracino; Elinor K Karlsson; Atiqur Rahman; Tahmina Shirin; Taufiqur R Bhuiyan; Fahima Chowdhury; Ashraful Islam Khan; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri; Jason B Harris
Journal:  Infect Immun       Date:  2015-01-05       Impact factor: 3.441

2.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

3.  Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera.

Authors:  Mohammad Arifuzzaman; Rasheduzzaman Rashu; Daniel T Leung; M Ismail Hosen; Taufiqur Rahman Bhuiyan; M Saruar Bhuiyan; Mohammad Arif Rahman; Farhana Khanam; Amit Saha; Richelle C Charles; Regina C LaRocque; Ana A Weil; John D Clements; Randall K Holmes; Stephen B Calderwood; Jason B Harris; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

Review 4.  Mucosal immunity to pathogenic intestinal bacteria.

Authors:  Araceli Perez-Lopez; Judith Behnsen; Sean-Paul Nuccio; Manuela Raffatellu
Journal:  Nat Rev Immunol       Date:  2016-02-22       Impact factor: 53.106

5.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 6.  Innate immunity at mucosal surfaces: the IRE1-RIDD-RIG-I pathway.

Authors:  Wayne I Lencer; Heidi DeLuca; Michael J Grey; Jin Ah Cho
Journal:  Trends Immunol       Date:  2015-06-17       Impact factor: 16.687

Review 7.  Immune responses to cholera in children.

Authors:  Daniel T Leung; Fahima Chowdhury; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Expert Rev Anti Infect Ther       Date:  2012-04       Impact factor: 5.091

8.  Cellular and cytokine responses to Salmonella enterica serotype Typhi proteins in patients with typhoid fever in Bangladesh.

Authors:  Saruar Bhuiyan; Abu Sayeed; Farhana Khanam; Daniel T Leung; Taufiqur Rahman Bhuiyan; Alaullah Sheikh; Umme Salma; Regina C LaRocque; Jason B Harris; Marcin Pacek; Stephen B Calderwood; Joshua LaBaer; Edward T Ryan; Firdausi Qadri; Richelle C Charles
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

9.  Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Authors:  Richelle C Charles; Isabelle J Hilaire; Leslie M Mayo-Smith; Jessica E Teng; J Gregory Jerome; Molly F Franke; Amit Saha; Yanan Yu; Paul Kováč; Stephen B Calderwood; Edward T Ryan; Regina C LaRocque; Charles P Almazor; Firdausi Qadri; Louise C Ivers; Jason B Harris
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

10.  Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines.

Authors:  Aqel Albutti; Stephanie Longet; Craig P McEntee; Shauna Quinn; Alex Liddicoat; Cristiana Rîmniceanu; Nils Lycke; Lydia Lynch; Susanna Cardell; Ed C Lavelle
Journal:  Vaccines (Basel)       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.